Direct HBV-specific CD8 T-cell response evolution during Peg-IFN-α therapy.

<p>Direct HBV-specific CD8 T cells measurements following Peg-IFN-α treatment using tetramers. (A) Representative dot plots of the tetramer labeling of HBc_18-27- and HBs_335-343-specific T cells (gated on CD8 T cells) before and 24 weeks after treatment in patients treated with nucleos(t)ide analog alone (<i>left panel</i>) or together with Peg-IFN-α (<i>right panel</i>). (B) Evolution of the basal percentages of HBc_18-27- (left panel) and HBs_335-343- (right panel) specific CD8 T cells in patients with CHB infection treated with nucleos(t)ide analog alone (<i>white bars</i>, n = 7) or together with Peg-IFN-α (<i>grey bars</i>, n = 7). The gray area represents the period of Peg-IFN-α administration.